Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employing a human lung reperfusion model

Respiratory Research

Volumn 6, Issue , 2005, Pages

  Freiwald, Matthias ^a   Valotis, Anagnostis ^a   Kirschbaum, Andreas ^b   McClellan, Monika ^c   Mürdter, Thomas ^c   Fritz, Peter ^d   Friedel, Godehard ^b   Thomas, Michael ^e   Högger, Petra ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Klinik Schillerhohe   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d ROBERT BOSCH HOSPITAL   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; DRUG METABOLITE; FLUORINATED HYDROCARBON; PRODRUG; PROPELLANT; VENTOLAIR; AEROSOL; BECLOMETASONE; GLUCOCORTICOID;

AEROSOL; ARTICLE; BIOLOGICAL MODEL; BRONCHUS; BRONCHUS TUMOR; CLINICAL ARTICLE; COMPARATIVE STUDY; DIALYSIS; DISSOLUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TISSUE LEVEL; HUMAN; HUMAN TISSUE; LUNG HOMOGENATE; LUNG LOBE; LUNG PERFUSION; METERED DOSE INHALER; PARTICLE SIZE; REPERFUSION; SCANNING ELECTRON MICROSCOPY; ABSORPTION; ADMINISTRATION AND DOSAGE; CLINICAL TRIAL; COMPUTER SIMULATION; IN VITRO STUDY; KINETICS; LUNG; METABOLIC CLEARANCE RATE; METABOLISM; PHARMACOKINETICS; PHYSIOLOGIC MONITORING; PROCEDURES;

ABSORPTION; AEROSOLS; BECLOMETHASONE; COMPUTER SIMULATION; DIALYSIS; GLUCOCORTICOIDS; HUMANS; IN VITRO TECHNIQUES; KINETICS; LUNG; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MONITORING, PHYSIOLOGIC; REPERFUSION;

EID: 25444506342     PISSN: 1465993X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1465-9921-6-21     Document Type: Article

References (35)

1. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 2. Bethesda, National Institutes of Health, National Heart, Lung and Blood Institute; 1997.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Bethesda, National Institutes of Health, National Heart, Lung and Blood Institute; 2002.
3. Högger P: Dose response and therapeutic index of inhaled corticosteroids in asthma. Curr Opin Pulm Med 2003, 9:1-8.
4. Rohatagi S, Appajosyula S, Derendorf H, Szefler S, Nave R, Zech K, Banerji D: Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004, 44:37-47.
5. Kelly HW, Nelson HS: Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003, 112:469-78; quiz 479.
6. Kelly HW: Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998, 102:S36-51.
7. Tronde A, Norden B, Marchner H, Wendel AK, Lennernas H, Bengtsson UH: Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci 2003, 92:1216-1233.
8. Tronde A, Baran G, Eirefelt S, Lennernas H, Bengtsson UH: Miniaturized nebulization catheters: a new approach for delivery of defined aerosol doses to the rat lung. J Aerosol Med 2002, 15:283-296.
9. Van den Bosch JM, Westermann CJ, Aumann J, Edsbacker S, Tonnesson M, Selroos O: Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993, 14:455-459.
10. Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P: Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997, 10:1496-1499.
11. Holz O, Zuhlke I, Einhaus M, Welker L, Kanniess F, Branscheid D, Nakashima M, Harrison LI, Jorres RA, Richter K, Magnussen H: Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulm Pharmacol Ther 2004, 17:233-238.
12. Derendorf H, Hochhaus G, Mollmann H: Evaluation of pulmonary absorption using pharmacokinetic methods. J Aerosol Med 2001, 14 Suppl 1:S9-17.
13. Würthwein G, Rohdewald P: Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990, 11:381-394.
14. Linder A, Friedel G, Fritz P, Kivisto KT, McClellan M, Toomes H: The ex-vivo isolated, perfused human lung model: description and potential applications. Thorac Cardiovasc Surg 1996, 44:140-146.
15. Mürdter TE, Sperker B, Kivisto KT, McClellan M, Fritz P, Friedel G, Linder A, Bosslet K, Toomes H, Dierkesmann R, Kroemer HK: Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res 1997, 57:2440-2445.
16. Mürdter TE, Friedel G, Backman JT, McClellan M, Schick M, Gerken M, Bosslet K, Fritz P, Toomes H, Kroemer HK, Sperker B: Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase. J Pharmacol Exp Ther 2002, 301:223-228.
17. Woodcock A, Acerbi D, Poli G: Modulite technology: pharmacodynamic and pharmacokinetic implications. Respir Med 2002, 96 Suppl D:S9-15.
18. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D: Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000, 106:1209-1226.
19. Zeidler M, Corren J: Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med 2004, 3:35-44.
20. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlback M, Tunek A, Brattsand R: Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998, 26:623-630.
21. Nave R, Sättele N, Meyer W, Fuhst R, Zech K: Formation of fatty acid conjugates of ciclesonide-active principle in the rat lung after 4-week inhalation of ciclesonide. Am J Respir Crit Care Med 2003, 167:A771.
22. Wiedmann TS, Bhatia R, Wattenberg LW: Drug solubilization in lung surfactant. J Control Release 2000, 65:43-47.
23. Davies NM, Feddah MR: A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 2003, 255:175-187.
24. Högger P: Comparison of the tissue affinity of glucocorticoids to human lung, nasal and skin tissue in vitro. Arzneimittelforschung 2001, 51:825-831.
25. Lipworth BJ, Jackson CM: Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. Br J Clin Pharmacol 1999, 48:866-868.
26. Harrison LI, Soria I, Cline AC, Ekholm BP: Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbonfree metered dose inhalers of beclomethasone dipropionate in adult asthmatics. J Pharm Pharmacol 1999, 51:1235-1240.
27. Harrison LI, Kurup S, Wagner C, Ekholm BP, Larson JS, Kaiser HB: Pharmacokinetics of beclomethasone 17-monopropionate from a beclomethasone dipropionate extrafine aerosol in adults with asthma. Eur J Clin Pharmacol 2002, 58:197-201.
28. Agertoft L, Laulund LW, Harrison LI, Pedersen S: Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol 2003, 35:192-199.
29. Seale JP, Harrison LI: Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir Med 1998, 92 Suppl A:9-15.
30. Leach CL, Davidson PJ, Boudreau RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998, 12:1346-1353.
31. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N: Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001, 51:400-409.
32. Levitt DG: The use of a physiologically based pharmacokinetic model to evaluate deconvolution measurements of systemic absorption. BMC Clin Pharmacol 2003, 3:1.
33. Daley-Yates PT, Baggen S, Tournant J, Pereira A: Beclomethasone dipropionate chlorofluorocarbon and hydrofluoroalkane metered dose inhalers: relationship between systemic exposure, dose, fine particle mass and particle size in healthy volunteers. Eur Respir J 1999, 14:P1358.
34. Foe K, Cutler DJ, Brown KF, Seale JP: Metabolism kinetics of beclomethasone propionate esters in human lung homogenates. Pharm Res 2000, 17:1007-1012.
35. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ: Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers. Chest 2002, 122:510-516.